ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
This study investigates whether contralateral delay activity occurs early in schizophrenia, possibly indicating that visual short-term memory deficits are a core feature of the disorder.
Data on thyroid hormone levels during the course of schizophrenia disorder are sparse. This study assessed the rate of thyroid hormone disorders in outpatients before and after a diagnosis of schizophrenia.
This study investigates whether proteomic biomarkers may aid in the prediction of the transition to psychotic disorder in the clinical high-risk state and adolescent psychotic experiences in the general population.
Since publication of the last full practice guideline and guideline watch on schizophrenia, there have been a multitude of studies on new pharmacological and nonpharmacological treatments for schizophrenia.
Short- to intermediate-term exposure to atypical antipsychotic medications may dysregulate adaptive immune responses, increasing susceptibility to respiratory infections like COVID-19.
Researchers report on the 52-week extension of the ENLIGHTEN-2 study that assessed the long-term safety and efficacy of treatment schizophrenia with olanzapine and samidorphan.
The socioeconomic character of a neighborhood, as well as accessibility of mental health care services, influence the wellbeing of patients with psychiatric disorders.
Patients with schizophrenia and a history of catatonia had greater deficits in the cognitive domains of immediate memory, verbal fluency, and processing speed compared to patients with schizophrenia alone.
Language disturbances in patients with schizophrenia were significantly associated with negative symptoms, and white matter integrity in language tracts was predicted by quantifiable speech patterns.
